Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice

Hirotada Suzuki, Akihide Ohkuchi, Shigeki Matsubara, Yuji Takei, Masato Murakami, Masabumi Shibuya, Mitsuaki Suzuki, Yasufumi Sato

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The first aim of our study was to develop a pregnant mouse model for preeclampsia using adenoviral vector containing mouse full-length soluble fms-like tyrosine kinase 1 (sFlt-1) but not truncated sFlt-1. The second aim was to evaluate effects of recombinant mouse (rm) vascular endothelial growth factor (VEGF) and rm placental growth factor (PlGF) on a preeclampsia model induced by adenoviral vector containing mouse full-length sFlt-1. We injected adenoviral vector containing mouse full-length sFlt-1 on day 8.5 or 9.5 of gestation into pregnant Institute of Cancer Research mice, resulting in hypertension, proteinuria, and similar glomerular histological changes as those seen in human preeclamptic women with glomerular endotheliosis on day 16.5 or 17.5 of gestation. The preeclampsia models were treated with 100 μg/kg of rmVEGF164 (n=5), 100 μg/kg of rmPlGF-2 (n=5), or vehicle (n=7) twice a day for 2 days IP. The rmVEGF164 treatment significantly decreased the mean blood pressure on day 16.5 or 17.5 of gestation compared with the vehicle treatment (85±4 versus 97±2 mm Hg; P=0.018). The rmPlGF-2 treatment also significantly decreased the mean blood pressure on day 16.5 or 17.5 of gestation compared with the vehicle treatment (86±3 versus 97±2 mm Hg; P=0.018). However, proteinuria was not affected by either rmVEGF164 or rmPlGF-2. In conclusion, we, for the first time, created a mouse preeclampsia model using mouse full-length sFlt-1. VEGF and PlGF may be promising for ameliorating hypertension in women with preeclampsia. Additional study of PlGF as a potential drug for preeclampsia is warranted.

Original languageEnglish
Pages (from-to)1129-1135
Number of pages7
JournalHypertension
Volume54
Issue number5
DOIs
Publication statusPublished - 2009 Nov 1

Keywords

  • Adenoviral vector
  • Animal models
  • Placental growth factor
  • Preeclampsia
  • Soluble fms-like tyrosine kinase 1
  • Therapy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice'. Together they form a unique fingerprint.

  • Cite this